Chuanchuan Ren
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Chuanchuan Ren has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
Shiqi Li
Department of Urology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
5 shared publicationsZhaokai Zhou
Department of Urology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
4 shared publicationsGuangyang Cheng
Department of Urology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
3 shared publicationsYan Wang
Department of Urology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
3 shared publicationsZhuo Ye
Department of Urology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
3 shared publicationsShuai Yang
Department of Urology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
2 shared publications
Latest Publications
- Open Access
- 5 August 2026
- Published by Wolters Kluwer Health in International Journal of Surgery Case Reports
- Vol. 138 (9) , 3412-3415
Renal small cell neuroendocrine carcinoma: a case report and literature review
Introduction and importance: Renal small-cell neuroendocrine carcinoma (renal SCNEC) is an exceedingly rare and highly aggressive tumor of the urinary system, originating from peptidergic neurons or neuroendocrine cells. The disease often presents with insidious clinical symptoms and lacks specific imaging features, which can delay diagnosis and predispose to distant metastases. Here, we report a case of renal SCNEC and describe its diagnosis, treatment, and outcomes, aiming to enhance clinical understanding and management of this rare condition. Case presentation: We report the case of a 64-year-old man who presented with left-sided flank pain without hematuria. Imaging studies revealed a mass in the left kidney. Percutaneous biopsy and immunohistochemical analysis confirmed the diagnosis of SCNEC. The patient received two cycles of neoadjuvant chemotherapy consisting of cisplatin and etoposide, followed by laparoscopic radical nephrectomy. Postoperative chemotherapy was administered according to the planned regimen. During 16 months of follow-up, no evidence of recurrence was observed. Discussion: Prompt recognition and diagnosis of renal SCNEC are crucial to prevent misdiagnosis and delayed treatment. Diagnosis relies on histopathology, immunohistochemistry, and careful evaluation of common metastatic sites, including lymph nodes, liver, and bones. Treatment should be individualized based on disease stage and the patient’s condition; for locally advanced renal SCNEC, platinum-based chemotherapy combined with radical surgery may be considered as part of a multimodal treatment strategy in selected patients. Given the rarity of this tumor, multidisciplinary collaboration and evidence-based research are essential to optimize management and establish standardized treatment guidelines. Conclusion: For patients with locally advanced renal SCNEC, platinum-based chemotherapy combined with radical surgery may provide a therapeutic option after multidisciplinary evaluation.
- 5 August 2026
- Published by Wolters Kluwer Health in International Journal of Surgery Case Reports
- Vol. 138 (9) , 3412-3415
Open AccessRenal small cell neuroendocrine carcinoma: a case report and literature review
Introduction and importance: Renal small-cell neuroendocrine carcinoma (renal SCNEC) is an exceedingly rare and highly aggressive tumor of the urinary system, originating from peptidergic neurons or neuroendocrine cells. The disease often presents with insidious clinical symptoms and lacks specific imaging features, which can delay diagnosis and predispose to distant metastases. Here, we report a case of renal SCNEC and describe its diagnosis, treatment, and outcomes, aiming to enhance clinical understanding and management of this rare condition. Case presentation: We report the case of a 64-year-old man who presented with left-sided flank pain without hematuria. Imaging studies revealed a mass in the left kidney. Percutaneous biopsy and immunohistochemical analysis confirmed the diagnosis of SCNEC. The patient received two cycles of neoadjuvant chemotherapy consisting of cisplatin and etoposide, followed by laparoscopic radical nephrectomy. Postoperative chemotherapy was administered according to the planned regimen. During 16 months of follow-up, no evidence of recurrence was observed. Discussion: Prompt recognition and diagnosis of renal SCNEC are crucial to prevent misdiagnosis and delayed treatment. Diagnosis relies on histopathology, immunohistochemistry, and careful evaluation of common metastatic sites, including lymph nodes, liver, and bones. Treatment should be individualized based on disease stage and the patient’s condition; for locally advanced renal SCNEC, platinum-based chemotherapy combined with radical surgery may be considered as part of a multimodal treatment strategy in selected patients. Given the rarity of this tumor, multidisciplinary collaboration and evidence-based research are essential to optimize management and establish standardized treatment guidelines. Conclusion: For patients with locally advanced renal SCNEC, platinum-based chemotherapy combined with radical surgery may provide a therapeutic option after multidisciplinary evaluation.
- Open Access
- 24 March 2026
- Published by Springer Nature in European Journal of Medical Research
Effects of unilateral ureteral obstruction on renal pelvic peristalsis and pacemaker cells in neonatal rats
- 24 March 2026
- Published by Springer Nature in European Journal of Medical Research
Open AccessEffects of unilateral ureteral obstruction on renal pelvic peristalsis and pacemaker cells in neonatal rats
- Open Access
- 25 February 2025
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 74 (4) , 1-16
Machine learning-derived prognostic signature integrating programmed cell death and mitochondrial function in renal clear cell carcinoma: identification of PIF1 as a novel target
Background The pathogenesis and progression of renal cell carcinoma (RCC) involve complex programmed cell death (PCD) processes. As the powerhouse of the cell, mitochondria can influence cell death mechanisms. However, the prognostic significance of the interplay between mitochondrial function (MF) and PCD remains unclear. Methods We collected sets of genes related to PCD and MF. Using a powerful machine learning algorithm framework, we investigated the relationship between MF and PCD in different cohorts of patients and developed a machine learning-derived prognostic signature (mpMLDPS) related to MF and PCD. Finally, the most appropriate prognostic markers for RCC were screened by survival analysis and clinical correlation analysis, and the effects on renal cancer cells were analysed in vitro. Results mpMLDPS was significantly correlated with the prognosis of RCC patients, and the prognosis was worse in the high mpMLDPS group, and this result was also validated in external independent cohorts. There were associations between mpMLDPS and immune checkpoints, tumour microenvironment, somatic mutations, and drug sensitivity. Finally, a novel RCC prognostic marker PIF1 was identified in model genes. The knockdown of PIF1 in vitro inhibited the progression of renal carcinoma cells. Conclusion mpMLDPS has great potential to serve as a reliable clinical signature to improve the accuracy and reliability of prognostic assessment in RCC patients, thereby choosing the appropriate therapeutic regimen in clinical practice. PIF1 is also expected to be a novel target for the clinical treatment of RCC.
- 25 February 2025
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 74 (4) , 1-16
Open AccessMachine learning-derived prognostic signature integrating programmed cell death and mitochondrial function in renal clear cell carcinoma: identification of PIF1 as a novel target
Background The pathogenesis and progression of renal cell carcinoma (RCC) involve complex programmed cell death (PCD) processes. As the powerhouse of the cell, mitochondria can influence cell death mechanisms. However, the prognostic significance of the interplay between mitochondrial function (MF) and PCD remains unclear. Methods We collected sets of genes related to PCD and MF. Using a powerful machine learning algorithm framework, we investigated the relationship between MF and PCD in different cohorts of patients and developed a machine learning-derived prognostic signature (mpMLDPS) related to MF and PCD. Finally, the most appropriate prognostic markers for RCC were screened by survival analysis and clinical correlation analysis, and the effects on renal cancer cells were analysed in vitro. Results mpMLDPS was significantly correlated with the prognosis of RCC patients, and the prognosis was worse in the high mpMLDPS group, and this result was also validated in external independent cohorts. There were associations between mpMLDPS and immune checkpoints, tumour microenvironment, somatic mutations, and drug sensitivity. Finally, a novel RCC prognostic marker PIF1 was identified in model genes. The knockdown of PIF1 in vitro inhibited the progression of renal carcinoma cells. Conclusion mpMLDPS has great potential to serve as a reliable clinical signature to improve the accuracy and reliability of prognostic assessment in RCC patients, thereby choosing the appropriate therapeutic regimen in clinical practice. PIF1 is also expected to be a novel target for the clinical treatment of RCC.
- Open Access
- 7 May 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-16
Predicting bladder cancer survival with high accuracy: insights from MAPK pathway-related genes
The mitogen-activated protein kinase (MAPK) pathway plays a critical role in tumor development and immunotherapy. Nevertheless, additional research is necessary to comprehend the relationship between the MAPK pathway and the prognosis of bladder cancer (BLCA), as well as its influence on the tumor immune microenvironment. To create prognostic models, we screened ten genes associated with the MAPK pathway using COX and least absolute shrinkage and selection operator (LASSO) regression analysis. These models were validated in the Genomic Data Commons (GEO) cohort and further examined for immune infiltration, somatic mutation, and drug sensitivity characteristics. Finally, the findings were validated using The Human Protein Atlas (HPA) database and through Quantitative Real-time PCR (qRT-PCR). Patients were classified into high-risk and low-risk groups based on the prognosis-related genes of the MAPK pathway. The high-risk group had poorer overall survival than the low-risk group and showed increased immune infiltration compared to the low-risk group. Additionally, the nomograms built using the risk scores and clinical factors exhibited high accuracy in predicting the survival of BLCA patients. The prognostic profiling of MAPK pathway-associated genes represents a potent clinical prediction tool, serving as the foundation for precise clinical treatment of BLCA.
- 7 May 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-16
Open AccessPredicting bladder cancer survival with high accuracy: insights from MAPK pathway-related genes
The mitogen-activated protein kinase (MAPK) pathway plays a critical role in tumor development and immunotherapy. Nevertheless, additional research is necessary to comprehend the relationship between the MAPK pathway and the prognosis of bladder cancer (BLCA), as well as its influence on the tumor immune microenvironment. To create prognostic models, we screened ten genes associated with the MAPK pathway using COX and least absolute shrinkage and selection operator (LASSO) regression analysis. These models were validated in the Genomic Data Commons (GEO) cohort and further examined for immune infiltration, somatic mutation, and drug sensitivity characteristics. Finally, the findings were validated using The Human Protein Atlas (HPA) database and through Quantitative Real-time PCR (qRT-PCR). Patients were classified into high-risk and low-risk groups based on the prognosis-related genes of the MAPK pathway. The high-risk group had poorer overall survival than the low-risk group and showed increased immune infiltration compared to the low-risk group. Additionally, the nomograms built using the risk scores and clinical factors exhibited high accuracy in predicting the survival of BLCA patients. The prognostic profiling of MAPK pathway-associated genes represents a potent clinical prediction tool, serving as the foundation for precise clinical treatment of BLCA.
- Open Access
- 25 January 2024
- Published by Springer Nature in Research Square
Predicting Bladder Cancer Survival with High Accuracy: Insights from MAPK Pathway-related Genes
The mitogen-activated protein kinase (MAPK) pathway plays a critical role in tumor development and immunotherapy. Nevertheless, additional research is necessary to comprehend the relationship between the MAPK pathway and the prognosis of bladder cancer (BLCA), as well as its influence on the tumor immune microenvironment.To create prognostic models, we screened ten genes associated with the MAPK pathway using COX and least absolute shrinkage and selection operator (LASSO) regression analysis. These models were validated in the Genomic Data Commons (GEO) cohort and further examined for immune infiltration, somatic mutation, and drug sensitivity characteristics. Finally, the findings were validated using The Human Protein Atlas (HPA) database and through Quantitative Real-time PCR (qRT-PCR).Patients were classified into high-risk and low-risk groups based on the prognosis-related genes of the MAPK pathway. The high-risk group had poorer overall survival than the low-risk group and showed increased immune infiltration compared to the low-risk group. Additionally, the nomograms built using the risk scores and clinical factors exhibited high accuracy in predicting the survival of BLCA patients.The prognostic profiling of MAPK pathway-associated genes represents a potent clinical prediction tool, serving as the foundation for precise clinical treatment of bladder cancer.
- 25 January 2024
- Published by Springer Nature in Research Square
Open AccessPredicting Bladder Cancer Survival with High Accuracy: Insights from MAPK Pathway-related Genes
The mitogen-activated protein kinase (MAPK) pathway plays a critical role in tumor development and immunotherapy. Nevertheless, additional research is necessary to comprehend the relationship between the MAPK pathway and the prognosis of bladder cancer (BLCA), as well as its influence on the tumor immune microenvironment.To create prognostic models, we screened ten genes associated with the MAPK pathway using COX and least absolute shrinkage and selection operator (LASSO) regression analysis. These models were validated in the Genomic Data Commons (GEO) cohort and further examined for immune infiltration, somatic mutation, and drug sensitivity characteristics. Finally, the findings were validated using The Human Protein Atlas (HPA) database and through Quantitative Real-time PCR (qRT-PCR).Patients were classified into high-risk and low-risk groups based on the prognosis-related genes of the MAPK pathway. The high-risk group had poorer overall survival than the low-risk group and showed increased immune infiltration compared to the low-risk group. Additionally, the nomograms built using the risk scores and clinical factors exhibited high accuracy in predicting the survival of BLCA patients.The prognostic profiling of MAPK pathway-associated genes represents a potent clinical prediction tool, serving as the foundation for precise clinical treatment of bladder cancer.
- Open Access
- 1 January 2024
- Published by Ivyspring International Publisher in International Journal of Medical Sciences
- Vol. 21 (11) , 2215-2232
Integration of proteomics and transcriptomics to construct a prognostic signature of renal clear cell carcinoma
Background: Protein information is often replaced by RNA data in studies to understand cancer-related biological processes or molecular functions, and proteins of prognostic significance in Kidney clear cell carcinoma (KIRC) remain to be mined.
- 1 January 2024
- Published by Ivyspring International Publisher in International Journal of Medical Sciences
- Vol. 21 (11) , 2215-2232
Open AccessIntegration of proteomics and transcriptomics to construct a prognostic signature of renal clear cell carcinoma
Background: Protein information is often replaced by RNA data in studies to understand cancer-related biological processes or molecular functions, and proteins of prognostic significance in Kidney clear cell carcinoma (KIRC) remain to be mined.